Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A.
Gogas H, et al.
Ann Oncol. 2021 Mar;32(3):384-394. doi: 10.1016/j.annonc.2020.12.004. Epub 2020 Dec 10.
Ann Oncol. 2021.
PMID: 33309774
Free article.
Clinical Trial.